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Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma,
characterized by immune system-dysregulated symptoms. Recent sequencing studies
have clarified the recurrent mutations in ras homology family member A (RHOA) and
in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2),
DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochon-
drial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL.
In this review, we focus on how this genetic information has changed the under-
standing of the developmental process of AITL and will in future lead to individual-
ized therapies for AITL patients.
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1 | INTRODUCTION
Recent progress in next-generation sequencing has provided emerging
evidence of characteristic genetic abnormalities in angioimmunoblastic
T-cell lymphoma (AITL). In this review, we provide insight into how the
biologic and clinical aspects of AITL are linked to its genetic features.
1.1 | Angioimmunoblastic T-cell lymphoma belongs
to a nodal T-cell lymphoma with T follicular helper
phenotype
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of malignant
lymphoma. Together with nodal peripheral T-cell lymphomas (PTCL)
with T follicular helper (TFH) phenotype and follicular T-cell lym-
phoma (FTCL), AITL belongs to nodal T-cell lymphoma with TFH phe-
notype, a newly proposed entity in the 2016 revised WHO
classification.1 Follicular helper T cells, a subset of helper T cells,
reside mainly in the follicles to support B-cell survival, proliferation,
maturation and migration.2 The TFH phenotype is determined by
expression of 2 or 3 markers that are expressed both in normal follic-
ular helper T cells and in tumor cells: CD279/programmed death-1
(PD1) and inducible T-cell costimulator (ICOS), T-cell coinhibitory and
costimulatory molecules; CD10, a membrane metalloendopeptidase;
B-cell lymphoma 6 protein (BCL6), a key transcription factor for TFH
development; C-X-C motif chemokine ligand 13 (CXCL13) and c-x-c
motif chemokine receptor 5 (CXCR5), a chemokine and chemokine
receptor; and signaling lymphocyte activation molecule (SLAM)-asso-
ciated protein (SAP), an adaptor protein for SLAM family receptors.1
Some gene mutations are commonly found in diseases categorized
into nodal T-cell lymphomas with TFH phenotype, and AITL-specific
mutations have been identified. (Note: See the Section below, “1.4.”)
1.2 | Angioimmunoblastic T-cell lymphoma is an
age-related lymphoma, presenting with symptoms of
immune system dysregulation
The incidence of AITL increases with age, with the median age at
onset reported to be 59-65 years.3 The prevalence of AITL in elderly
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individuals may be tightly linked to the age-related premalignant
mutations in AITL. (Note: See the Section, “1.9.”) AITL patients dis-
play generalized lymphadenopathy, a characteristic symptom of
malignant lymphomas. Furthermore, the symptoms suggestive of
immunologic hyperactivation are also present in AITL: fever, rash,
Coombs test-positive hemolytic anemia and polyarthritis.3 Again,
these immune system-related symptoms may be attributable to
genetic events involving multiple components of T-cell receptor
(TCR) signaling pathways. (Note: See the Section below, “1.4.”)
1.3 | Massive infiltration of accessory cells occurs
in angioimmunoblastic T-cell lymphoma
Various immune cells, including nontumor reactive T cells, B cells
(some of which are infected by Epstein–Barr virus [EBV]), eosinophils
and macrophages, invade AITL tissues.3 Moreover, the blood vessels
are markedly increased and often surrounded by AITL tumor cells. In
addition, follicular dendritic cells (FDC) are also prominently present
near the tumor cells and blood vessels.3 As mentioned above, AITL
tumor cells resemble cytokine-producing and chemokine-producing
TFH cells.4 Cytokines and chemokines released from TFH-like tumor
cells may recruit immune cells, blood vessels and FDC into AITL tis-
sues, and activate them to further produce cytokines and chemo-
kines. This positive circuit of cytokines and chemokines may
exacerbate the trafficking of these cells into AITL tissues. For
instance, the CXCL13 and its receptor CXCR5 network is thought to
promote recruitment of B cells and FDC as well as tumor cells into
AITL tissues.3 Vascular endothelial growth factor (VEGF), a cytokine
that promotes angiogenesis, is expressed in both tumor and vascular
endothelial cells.5 Cytokine-producing helper T17 (Th17) cells as well
as CD8-positive T cells are also enriched in AITL tissues.6 Mast cells
in AITL tissues function as producers of VEGF, to recruit endothelial
cells,7 and of interleukin-6 (IL-6), to proliferate Th17 cells.8
Although the cytokine and chemokine circuit originating from
TFH-like tumor cells may account for the massive infiltration of
immune cells into AITL tissues, novel genetic evidence indicated that
tumor-infiltrating cells may not be entirely attributable to the reac-
tive process.9 The infiltrating B cells in AITL tissues had gene muta-
tions distinct from those found in tumor cells.9 The genetic events in
tumor-infiltrating cells may synergize with the cytokine-and chemo-
kine-mediated reactions to produce the pathologic features of AITL.
(Note: See the Section below, “1.10.”)
1.4 | Ras homology family member A, epigenetic
regulators, and T-cell signaling molecules are the
main players in the genetic abnormalities of
angioimmunoblastic T-cell lymphoma
Recent genetic studies identified recurrent mutations in ras homolog
family member A (RHOA) (50%-70%)10-12 and in genes encoding the
epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2) (47%-
83%),10,13 DNA methyltransferase 3 alpha (DNMT3A) (20%-30%)10,11,14
and isocitrate dehydrogenase 2, mitochondrial (IDH2) (20%-45%),10,15
as well as the components of the TCR signaling pathways, phospholi-
pase C gamma 1 (PLC c) (14%),16 CD28 (9%-11%),16,17 FYN protoonco-
gene, Src family tyrosine kinase (FYN) (3%-4%)11,16 and vav guanine
nucleotide exchange factor 1 (VAV1) (5%)16 in AITL (Table 1).
Almost all the RHOA mutations found in AITL were p.G17V (G17V
RHOA mutations).10-12 G17V RHOA mutations were commonly
observed in the other nodal T-cell lymphomas with TFH phenotype:
57%-62% of nodal PTCL with TFH phenotype10,14 and 60% of FTCL,14
while they were quite rare in other diseases. In contrast, TET2 and
DNMT3A mutations were found in a broad range of hematologic
malignancies,18 and even in healthy elderly individuals.19,20 (Note: See
the Section below, “1.9.”) Among T-cell lymphomas, TET2 mutations
were more prevalent in nodal T-cell lymphomas with TFH phenotype
than those without TFH phenotype (nodal PTCL with TFH phenotype
vs FTCL vs PTCL without the TFH phenotype: 64% vs 75% vs 17%).14
IDH2 mutations were also found in myeloid malignancies. However,
IDH2 mutations were not detectable in the other T-cell lym-
phomas,10,15 even those with the TFH phenotype,14 suggesting that
IDH2 mutations may provide AITL with its specific pathologic features.
The mutations involving components of the TCR signaling pathways
were commonly observed in nodal PTCL with TFH phenotype,16
although CD28 mutations were specific to AITL.17 Notably, the AITL
genome exhibited a specific combination of these mutations: the
RHOA-mutated samples also had TET2 mutations, while a part of the
RHOA and TET2-mutated samples had IDH2 mutations.10 These com-
binations may have a synergistic effect on oncogenesis.
1.5 | Diagnostic impact of G17V ras homology
family member A mutations
As mentioned above, G17V RHOAmutations were commonly identified
in nodal T-cell lymphomas with the TFH phenotype,10,14 although they
were also observed in a few cases of adult T-cell leukemia/lymphoma
TABLE 1 Recurrent gene mutations in AITL
Frequencies (%) References
RAS superfamily
RHOA 50-70 10-12
Epigenetic regulators
TET2 47-83 10,13
DNMT3A 20-30 10,11,14
IDH2 20-45 10,15
TCR signaling pathway
PLCc 14 16
CD28 9-11 16,17
FYN 3-4 11,16
VAV1 5 16
AITL, angioimmunoblastic T-cell lymphoma; DNMT3A, DNA methyltrans-
ferase 3 alpha; FYN, FYN protooncogene, Src family tyrosine kinase;
IDH2, isocitrate dehydrogenase 2, mitochondrial; PLCc, phospholipase C
gamma 1; RHOA, ras homolog gene family, member A; TCR, T-cell recep-
tor; TET2, tet methylcytosine dioxygenase 2; VAV1, vav guanine nucleo-
tide exchange factor 1.
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(ATLL),21 which can be distinguished by its integration of human T-lym-
photropic virus (HTLV)-1. Therefore, G17V RHOA mutations serve as a
genetic indicator to detect nodal T-cell lymphomas with the TFH phe-
notype. The tumor ratio is sometimes low because of the prominent
reactive cells, which makes it difficult to detect G17V RHOA mutations
by direct sequencing. It is reported that the allele-specific PCR (AS-
PCR) assay is an easy-to-use method to detect G17V RHOA muta-
tions.22 The positive and negative concordance rates between AS-PCR
and amplicon-based deep sequencing were as high as 95%.22 G17
RHOA mutations were also detectable in cell-free DNA, enabling their
application in noninvasive diagnostic testing of AITL.23
1.6 | Oncogenic roles of ras homology family
member A mutations are under investigation
RHOA is a small guanine nucleotide triphosphate (GTP)-binding pro-
tein. RHOA mediates fundamental biologic processes, including cell
mortality, adhesion, the cell cycle and cytokinesis. While the func-
tions of RHOA in peripheral T cells have not been fully elucidated,
the conditional deletion of the RhoA gene under the control of the
CD2 or Lck promoters resulted in severe defects in thymocyte devel-
opment in mice.24 RHOA carries out a switch-like function by mak-
ing a round trip between the guanine nucleotide diphosphate (GDP)-
bound inactive state and the guanine nucleotide triphosphate (GTP)-
bound active state.25 The 17th glycine of RHOA is located at a posi-
tion essential for binding to GTP.10 In a Rhotekin pull-down assay to
detect GTP-bound RHOA, the G17V RHOA mutant was not bound
to GTP,10-12 indicating that the G17V RHOA mutant does not medi-
ate classical RHOA signaling. Curiously, the p.K18N mutant existing
in a few AITL samples had higher GTP-binding capacity.16 Therefore,
the oncogenic roles of the G17V RHOA mutant in AITL development
may not be due to the disruption of classical RHOA signaling.
Rather, the existence of mutations at a single amino acid strongly
suggests that the G17V mutant acquires a specific oncogenic role.
Recently it was reported that the G17V mutant activated TCR path-
way through direct binding to VAV1, an essential mediator of the
TCR pathway.26 Together with the frequent mutations in TCR path-
way, aberrant activation of TCR pathway by the G17V RHOA
mutant may be a clue for AITL development. (See the Section, “1.8.”)
Other RHOA mutations are reported in diffuse-type gastric carci-
noma,27 Burkitt lymphoma28 and ATLL.21 The most frequent RHOA
mutations in gastric carcinoma and Burkitt lymphoma were the
p.Y42C and p.R5Q mutations,27,28 while the p.C16R mutations were
the most frequent in ATLL.21 Whether these various RHOA muta-
tions share common downstream molecules essential for oncogene-
sis remains to be elucidated.
1.7 | Mutations in epigenetic regulators
TET2 encodes a methylcytosine, dioxygenase, to convert methylation
cytosine (mC) to hydroxymethylcytosine (hmC), formylcytosine (fC) and
carboxylcytosine (CaC).29 These modified cytosines function as
intermediates of the passive or active demethylating process, and as
epigenetic marks.29 Nonsense and frameshift mutations were dis-
tributed throughout the entire TET2 protein, while missense mutations
almost always existed at the C-terminal catalytic domain in AITL, as in
myeloid malignancies.10,13 This distribution of mutations indicates that
TET2 mutations are loss-of-function mutations. DNMT3A encodes a
DNA methyltransferase, which methylates nonmethylated CpG.
DNMT3Amutations were distributed across the entire protein. Hotspot
p.R882 mutations accounted for approximately 15% of DNMT3Amuta-
tions in AITL,10 while they accounted for more than half of the muta-
tions in myeloid malignancies.30 The p.R882H DNMT3A mutant was
shown to have reduced methyltransferase activity and also to domi-
nant-negatively inhibit wildtype DNMT3A by interference with
homotetramer formation.31 DNMT3A and TET2 mutations were some-
times seen together in AITL32 as well as in myeloid malignancies,
although the epigenetic effects were opposite. The synergistic effects
of TET2 and DNMT3A loss on AITL development were shown using a
mouse model33 (Note: See the Section below, “1.11.”) In AITL, IDH2
mutations were exclusively present at the p.R172 position,10,15 while
both p.R140 and p.R172 IDH2 mutations and p.R132 IDH1 mutations
were seen in myeloid malignancies.34 Under physiologic conditions,
IDH enzymes convert isocitric acid to a-ketoglutaric acid (a-KG) in an
NADP+-dependent manner. a-KG functions as an intermediate
metabolite of the tricarboxylic acid (TCA) cycle and also as a substrate
in enzymes that are not included in the TCA cycle. IDH mutants have
been shown to aberrantly produce D-2-hydroxyglutarate (D-2-HG), a
so-called oncometabolite. D-2-HG inhibits the a-KG-dependent enzy-
matic activity of dioxygenases, including the TET family of proteins and
Jumonji-C histone demethylases.34 As mentioned above, IDH2 and
TET2 mutations coexist in AITL samples, suggesting that TET proteins
other than TET2 or Jumonji-C histone demethylases may be the main
targets of the oncometabolite. In fact, it was shown that both DNA
methylation and histone H3K27 methylation were more prominent in
AITL samples with TET2 and IDH2 mutations than in those with TET2/
without IDH2mutations.35
Hypomethylating reagents are currently in clinical use for
myelodysplastic syndrome. These reagents tend to be more effective
in TET2-mutated cases than in TET2 wildtype cases. Highly prevalent
TET2 mutations in AITL suggest that AITL may also respond to these
hypomethylating reagents. In fact, several AITL cases effectively
treated with azacytidine have been reported.36,37
1.8 | T-cell receptor-related mutations
Upon TCR stimulation, CD28 functions as a costimulatory molecule
to support full and sustained T-cell activation. Subsequently, FYN, a
Src kinase, is activated, resulting in further phosphorylation of down-
stream molecules (ie PLCc and VAV1). VAV1, known as a GEF pro-
tein, also functions as an adaptor to facilitate and activate the TCR
proximal signaling complex, involving PLCc and SLP-76. PLCc cat-
alyzes phosphatidylinositol 4, 5-bisphosphate (PI(4,5)P2) into inositol-
1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG), leading to intra-
cellular signal transduction through calcium mobilization and
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activation of protein kinase C (PKC). Activating mutations were
observed in these players participating in TCR signaling.
CD28 mutations were accumulated at 2 hotspots, p.D124 and
p.T195.16,17 The p.D124 mutant was shown to have higher affinity
for the ligands CD80 and CD86,17 while the p.T195 mutant had
higher affinity for the intracellular adaptor proteins GADS/GRAP2
and GRB2.17,38 The CTLA4-CD2839 and ICOS-CD28 fusion genes17
have also been described. FYN mutations found in the SH2 domain
and C terminus were activating mutations, presumably through the
disruption of the intramolecular inhibitory interaction between the
SH2 domain and the C terminus.11 PLCc mutations were found in
several functional motifs, including the PI-PLC, SH2, SH3 and C2
domain. PLCc mutations were also shown to be activating muta-
tions,16 although the biologic consequence of these mutations has
yet to be clarified. VAV1 mutations were found at several hot-
spots,16 although the oncogenic mechanisms of these mutations
remain unclear. In addition, the C-terminal portion of VAV1, partici-
pating in intramolecular inhibition, was recurrently deleted by 2 dis-
tinct mechanisms: an alternative splicing mechanism resulting from
in-flame deletion of the N-terminal site of the CSH3 domain40 and
formation of fusion genes with several distinct partners.40,41
Although the genetic evidence suggests that activation of TCR
signaling by gene mutations may play a role in the symptoms and
progression of AITL, it has not been exactly proven by in vivo exper-
iments. Cyclosporin A, a calcineurin inhibitor that blocks TCR signal-
ing, is widely used for the treatment of immune system-mediated
diseases.42 Cyclosporin A as a single reagent43 or with other
immunosuppressive reagents44 was shown to effectively ameliorate
the progression and symptoms of AITL. The effectiveness of cyclos-
porine A supports the hypothesis that activation of TCR signaling
may actually contribute to AITL progression and that it can be a can-
didate pathway in targeted therapies.
1.9 | Age-related mutations may precede
angioimmunoblastic T-cell lymphoma
Hematologic malignancies are classified according to their normal
counterparts; that is, normal cells sharing the characteristics of tumor
cells. Furthermore, they had previously been thought to originate
from their normal counterparts; for example, AITL had been thought
to originate from its normal counterpart, TFH cells. However, we
now believe that at least some hematologic malignancies including
AITL may originate from immature blood cells.18 The TET2 and
DNMT3A mutations detected in tumor cells were also recognized in
the tumor-free peripheral blood cells,45 bone marrow cells10,32,45 and
hematopoietic progenitors32,45 of AITL patients. Some patients
simultaneously or serially developed both AITL and myeloid malig-
nancies. Identical TET2 and DNMT3A mutations were reported to be
present in both diseases, suggesting that both diseases originate
from premalignant cells harboring these mutations.32,37 When a
nationwide survey was conducted to examine the cooccurrence of
myeloid and lymphoid malignancies, 72 cases were identified: 45
cases having the diseases simultaneously and 27 cases
sequentially.46 Whether the multiple diseases in these cases actually
had common ancestors remains to be elucidated.
Finally, somatic mutations were also detected even in healthy
individuals.19,20 Mutation frequencies were reportedly increased with
age: by 5% for those in their 60s, by 10% to 15% for those in their
70s, and by 10% to 25% for those in their 80s.19,20 Somatic muta-
tions were also detected in 95% of individuals aged 50-60 years
when the detection sensitivity was set at 0.0003 variant allele fre-
quencies (VAF).47 The most frequently mutated genes in the healthy
individuals were DNMT3A, TET2 and ASXL1.19,20 Although these
mutations were first found in hematologic malignancies, they may be
defined as age-related mutations. The status of having somatic muta-
tions without any evidence of hematologic diseases is called clonal
hematopoiesis of indeterminate potential (CHIP).48 CHIP was related
to a high incidence of blood cancers and inferior overall survival.19,20
The presence of premalignant mutations in AITL patients suggests
that CHIP may precede AITL in most cases. However, the actual
incidence rate of AITL caused by CHIP has not been determined.
Indeed, because of its rarity, it would be tough to determine the
incidence rate.
TET2 and DNMT3Amutations themselves in premalignant cells may
not be sufficient to induce AITL development. Multiple TET2mutations
were frequently observed in AITL tissues,10 while TET2mutations were
heterozygous in CHIP as well as in myeloid malignancies. When the dis-
tribution of TET2 mutations were examined in 19 AITL/PTCL samples
using laser microdissection followed by targeted sequencing, 10 sam-
ples had 2 distinct TET2 mutations, while 6 had one TET2 mutation.9
Although both mutations were determined as premalignant mutations
in 5 of the samples, the 5 samples had 1 mutation as a premalignant
mutation and the other as a tumor-specific mutation.9 These observa-
tions suggest that the profound defect in TET2 function may skew pre-
malignant cells into tumor cells. In addition, RHOA and IDH2 mutations
were detected in tumor cells,9 suggesting that acquisition of these
mutations together with preexisting TET2 and DNMTAmutations leads
to AITL development.
1.10 | Clonal evolution in tumor-infiltrating B cells
As mentioned above, the massive infiltration of immune cells into
AITL tissues is partly due to the cytokine and chemokine storm,
beginning from the cytokine and chemokine production from tumor
cells and being amplified by the tumor-infiltrating inflammatory cells.
At the same time, it is well known that rearrangement of
immunoglobulin (Ig) genes in addition to that of TCR genes is found
in 0% to 40% of AITL samples,3 suggesting that B cells as well as T-
lineage tumor cells proliferate clonally in AITL tissues. EBV infection
observed in 66% to 86% of cases49–51 may partly explain the clonal
expansion of B cells. Notably, AITL and B-cell lymphomas simultane-
ously cooccur as composite lymphomas, or serially during the disease
course in up to 20% of AITL patients.52,53 Although EBV may
account for oncogenic mechanisms of EBV-positive B-cell lym-
phomas, EBV is negative in a substantial proportion of B-cell lym-
phomas.52–54
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TET2-and DNMT3A-mutated premalignant cells may be differenti-
ated into tumor-infiltrating B cells as well as tumor cells. In fact,
when the distribution of these mutations was examined in AITL tis-
sues using laser microdissection followed by targeted sequencing,
TET2 mutations were detected even in B cells as well as in tumor
cells in 15 of the 16 cases, and DNMT3A mutations were also found
in both B cells and tumor cells in 4 of the 7 cases (Figures 1 and 2).9
Remarkably, B-cell specific mutations were also identified.9 In partic-
ular, all 3 NOTCH1 mutations exhibited B-cell-specific distribution
(Figures 1 and 2). These observations suggest that B cells residing in
AITL tissues may have undergone clonal selection.
1.11 | Angioimmunoblastic T-cell lymphoma mouse
model mimicking the human angioimmunoblastic T-
cell lymphoma genome
The impact of genetic events on AITL development can be examined
using mouse models. As mentioned above, loss-of-function TET2muta-
tions were highly frequent in AITL.10 It was reported that TFH cells
were gradually increased and finally T-cell lymphomas with the TFH
phenotype developed at long latencies in Tet2 gene-trap mice.55 The
lymphoma cells exhibited increased methylation at the transcriptional
start site (TSS) regions, gene bodies and CpG islands, and decreased
hydroxymethylation at the TSS regions.55 In particular, the negative
regulatory region of BCL6 encoding a fate-determinant of TFH cells
was highly methylated in lymphoma cells.55 Decitabine treatment
results in demethylation of the loci, accompanying downregulation of
Bcl6 expression.55 Furthermore, human PTCL samples also had hyper-
methylation of the corresponding loci, especially when they had TET2
mutations.56 The impaired TET2 function may induce BCL6 upregula-
tion, resulting in the skewed differentiation toward TFH cells in both
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humans and mice. The synergistic effect of TET2 and DNMT3A muta-
tions on AITL development was proven using mice transplanted with
Tet2-null hematopoietic stem/progenitor cells expressing genes trans-
duced with R882H DNMT3A mutant cDNA.33 The synergistic effect of
TET2 and G17V RHOA mutations, the most frequent combinations in
human AITL, was also shown by mice transplanted with Tet2-null T cells
expressing genes transduced with G17V RHOAmutant cDNA.57
2 | CONCLUSION
The biology of AITL has become gradually understood as a result of
the multistep and multilineage tumorigenesis concept: premalignant
cells having epigenetic mutations evolve into tumor and tumor-infil-
trating cells through clonal selection of the mutated cells. The multi-
step and multilineage acquisition of mutations may contribute to the
formation of the striking pathologic features of AITL. Concurrently,
these characteristic gene mutations have begun to change the clini-
cal approach to AITL. G17V RHOA mutations will be used in a clini-
cal setting to assist diagnosis of AITL. This genetic information may
lead to individualized therapies for AITL patients in future.
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